AKT1 and Hearing impairment: To the best of our knowledge, while similar studies may be ongoing globally, this study is the first to show that ibrutinib can cause hearing impairment by blocking the GPR83 or EGFR–AKT pathways involved in HC death (Figure 4; Supplementary Figure S1).